Wall Street is still pricing $IBRX like a niche bladder cancer play.
They’re missing the shift: global regulators just validated ANKTIVA as a mult-tumor oncology platform. 🧵
U.S. models focus heavily on NMIBC bladder cancer, but international approvals in Saudi Arabia and the UAE expanded the label to include metastatic lung cancer (NSCLC).
That shifts ANKTIVA from a niche market into one of the largest global TAMs in oncology.
Why it matters: As an IL-15 superagonist, ANKTIVA rescues NK and T-cells to enhance checkpoint inhibitors.
The international data proves it functions as a universal “immune backbone” across solid tumors - not just a single-indication drug.
With 34 international authorisations and 8 consecutive quarters of U.S. revenue growth ($50.7M in Q2), global rollout is funding the pipeline ahead of the Jan 2027 sBLA target.
Single-drug biotechs get standard multiples. Multi-tumor platforms get re-rated.
Will U.S. lung cancer data or international revenue force the re-rating first?
$IBRX
@Betterment_Lab Good shout for people who like property but not the hassle. Worth knowing REITs can fall like any other equity in a selloff, so they behave less like bricks and mortar than people expect.
@carrioresearch Wild number. The flip side of Nvidia being such a big chunk of the index is that plenty of people who think they're diversified in an S&P tracker have more riding on one chip company than they realise.
@Ugw_Onyinye Agree on watching the data rather than the candle. Gold dropping on a risk-off day is a bit counterintuitive too. Could be people selling what's up to cover losses elsewhere.
@dbdegn Nobody knows, honestly. What I'd watch is whether earnings forecasts start getting cut or it's just multiples coming down. Painful either way, but very different animals.
@StevenGWalker74 Worth saying index funds only buy once a stock is actually added to the index, which normally isn't straight after an IPO, though the rules vary by index. Active managers choosing to buy is a different matter.
@EmmanuelInvest Usually it's the multiple doing the damage. If the starting valuation was stretched, years of earnings growth can be eaten up by the market simply deciding to pay less for them.
@DZEcon Yen and bonds both catching a bid is the classic risk-off pairing. Be interesting to see if it sticks into next week or reverses as fast as the AI trade did.
@tradingfloorai Hongkong Land raising guidance on a day like this is a nice reminder there's still plenty of steady news in London away from the AI drama.
@mZbay_soylevol Fair distinction. 2008 was leverage in households and banks, whereas this is mostly big tech spending its own cash. The bit I'd watch is the private credit and off-balance-sheet financing around data centres, since that's where it could spread.
@ModernDayInves There's a lot of truth in that. Picking stocks is fine if you genuinely have a reason for each one, but a lot of people find out in a drawdown they were holding the index with extra steps and more volatility.
@CV_Investing Amazing how quickly a strong year can shrink to almost flat. Shows how much of the Nasdaq's gain was riding on a handful of names and the rate outlook staying friendly.
@njperez Agree, the debt side is what I'd watch most. When GPUs are the collateral and they lose value quickly, the interest bill doesn't shrink with them. Contract length and utilisation matter more than headline revenue growth here.
@JustOutLier Tencent's a good test case because the core business throws off so much cash. If even they're going cash-negative on AI, the question is how long shareholders put up with it. Did they say anything about capex peaking?
@QuantAlphaXXX Record backlog alongside a margin warning is an interesting combo. Sounds more like a cost problem than a demand one, so I'd be curious whether the market's pricing in a cyclical peak or something more lasting.
@ElioWIF One of the best lessons in markets. Being right most of the time doesn't help if one bad stretch can wipe you out. Leverage turns a temporary drawdown into a permanent loss.
@gulVasikova The recurring revenue is what makes Palo Alto interesting to me. Security tends to be one of the last budgets companies cut, so strong guidance in a nervous market says a lot about how sticky those contracts are.
@AlphaBinCap Makes sense, money chasing US AI names has to buy dollars first. Worth UK investors in global trackers remembering that currency moves can flatter or drag on returns, and it works both ways.
@Neha_Goswamii That's the bit that hits households first. Anyone on a variable rate or with a mortgage deal ending soon feels a hike long before it shows up in the inflation figures.
@AIWithAlia First-day moves tell you more about demand for the shares than what the business is worth. The real test is a few quarters of results as a public company, when everyone can see the margins.
@financespotnews Will be interesting after TJX's quarter. If Ross shows the same strength it says a lot about shoppers trading down rather than simply spending less.